| 8.01 -4.64 (-36.68%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.35 |
1-year : | 9.75 |
| Resists | First : | 7.15 |
Second : | 8.35 |
| Pivot price | 6.53 |
|||
| Supports | First : | 6.59 |
Second : | 6.25 |
| MAs | MA(5) : | 6.71 |
MA(20) : | 6.6 |
| MA(100) : | 6.43 |
MA(250) : | 7.75  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 52.7 |
D(3) : | 52.8 |
| RSI | RSI(14): 60.8 |
|||
| 52-week | High : | 11.17 | Low : | 5.17 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CYCCP ] has closed Bollinger Bands are 26.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.16 - 7.2 | 7.2 - 7.24 |
| Low: | 6.4 - 6.45 | 6.45 - 6.49 |
| Close: | 6.89 - 6.96 | 6.96 - 7.03 |
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Tue, 19 Mar 2024
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript - Seeking Alpha
Tue, 30 Jan 2024
Cyclacel Pharmaceuticals Appoints Brian Schwartz, M.D. as Chief Medical Officer - citybiz
Thu, 20 Jul 2017
CYCC Stock Price and Chart — NASDAQ:CYCC - TradingView
Tue, 04 Apr 2017
Why Cyclacel Pharmaceuticals Inc (CYCC) is in the Spotlight - Insider Monkey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -33.9 % |
| Return on Equity (ttm) | -49.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.39 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -2.62 |
| PEG Ratio | 0 |
| Price to Book value | 1.64 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2022-01-31 |
| Ex-Dividend Date | 2021-10-13 |
|
|
|
|
|
|
|
|
|